A phase I study of RYI-018 in healthy and non-alcoholic fibrotic liver disease (NAFLD) patients
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Namacizumab (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; First in man; Therapeutic Use
- 11 Jan 2017 According to a Bird Rock Bio media release, company received approval to initiate this study.
- 27 Oct 2016 According to Bird Rock Bio media release, company has submitted Clinical Trial Authorization to initiate this study.
- 27 Oct 2016 According to Bird Rock Bio media release, data from the SAD and MAD are anticipated to be available in Q1 2017 and Q4 2017 respectively.